Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metaproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.85 |
| ▸ | MAPT | P10636 | 7/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.85 |
| ▸ | TSHR | P16473 | 5/20 | 0.85 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.85 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.85 |
| ▸ | MEN1 | O00255 | 5/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.85 |
| ▸ | MTOR | P42345 | 3/20 | 0.85 |
| ▸ | LMNA | P02545 | 3/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metaproterenol SCHEMBL9051746 | 0.93 | BLM (0.79) | ADRB2MAPTTDP1KDM4ETSHR | |
| Isoproterenol SCHEMBL4165 | 0.92 | MAPT (1.00) | ADRB2MAPTTDP1KDM4ETSHR | |
| Isoproterenol SCHEMBL29386243 | 0.92 | MAPT (1.00) | ADRB2MAPTTDP1KDM4ETSHR | |
| Isoproterenol SCHEMBL4166 | 0.92 | MAPT (1.00) | ADRB2MAPTTDP1KDM4ETSHR | |
| Levisoprenaline SCHEMBL29620666 | 0.92 | MAPT (1.00) | ADRB2MAPTTDP1KDM4ETSHR | |
| Isoproterenol SCHEMBL29519146 | 0.92 | MAPT (1.00) | ADRB2MAPTTDP1KDM4ETSHR | |
| Isoproterenol SCHEMBL3253794 | 0.92 | MAPT (1.00) | ADRB2MAPTTDP1KDM4ETSHR | |
| Levisoprenaline SCHEMBL250806 | 0.92 | MAPT (1.00) | ADRB2MAPTTDP1KDM4ETSHR | |
| Terbutaline SCHEMBL1417928 | 0.91 | ADRB2 (0.70) | ADRB2MAPTTDP1KDM4ETSHR | |
| Isoproterenol SCHEMBL6151626 | 0.91 | MAPT (0.97) | ADRB2MAPTTDP1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633717-B1 | P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| EP-1660461-B1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-7408065-B2 | P2X7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-7227038-B2 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| WO-2005021513-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005014529-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004108692-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108717-A1 | SULPTIONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108690-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004074224-A1 | ADAMANTANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | disclosed |
| US-5260333-A | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions | BRISTOL MYERS SQUIBB COMPANY (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0321613-A1 | The effect of a combination of a beta-adrenergic agonist and certain histamine H1- and/or H2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions | Bristol-Myers Company (US) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | P2RX2, P2RX3, P2RX7 | ADRB2 33/4885MAPT 2772/4885TDP1 1989/4885 |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | CCL2, CCL11, CCR2 | ADRB2 3039/4885MAPT 2637/4885TDP1 3693/4885 |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | ADRB2 204/4885MAPT 1761/4885TDP1 1555/4885 |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | P2RX7, P2RX1, P2RX2 | ADRB2 56/4885MAPT 3429/4885TDP1 3344/4885 |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | ADRB2 56/4885MAPT 3429/4885TDP1 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.